Hashimoto's thyroiditis, nodular goiter or follicular adenoma combined with papillary thyroid carcinoma play protective role in patients

Hashimoto's thyroiditis, nodular goiter or follicular adenoma combined with papillary thyroid carcinoma play protective role in patients
复制标题

对桥本甲状腺炎、结节性甲状腺肿或滤泡性腺瘤合并甲状腺乳头状癌患者起到保护作用

DOI:
10.4149/neo_2018_170428n317
复制
发表时间:
2018-01-01
期刊:
影响因子:
3
通讯作者:
Zhang, R.
Zhang, R.
中科院分区:
医学4区
文献类型:
--
作者:
Ma, H.;Li, L.;Zhang, R.

文献摘要

被引文献

相似文献

甲状腺乳头状癌(PTC)常合并其他类型的甲状腺疾病,如桥本甲状腺炎(HT)、结节性甲状腺肿(NG)、滤泡性腺瘤(FA)等。然而,这些疾病在PTC肿瘤发生和发展中的作用尚不清楚。本研究收集了563例PTC患者,根据病理诊断分为单纯PTC(PTC)和PTC合并其他甲状腺疾病(PTC+)两组。比较PTC和PTC+患者的临床病理特征和BRAF(V600 E)突变情况。我们的数据显示,PTC和PTC+之间的性别(p=0.007)、肿瘤直径(5 mm,p=0.012; 1 cm,p=0.042)、淋巴结转移(p=0.000)和BRAF(V600 E)突变状态(p=0.001)存在统计学显著差异。PTC+患者的淋巴结转移率较低,即使PTC结节直径大于5 mm(p=0.005)或≥ 1 cm(p=0.049)或BRAF(V600 E)突变(p=0.001)。结论:HT、NG和FA是PTC患者的保护性因素,PTC+患者的淋巴结转移率和BRAF(V600 E)突变率均低于单纯PTC患者。
Papillary thyroid carcinoma (PTC) is often combined with other types of thyroid disease, such as Hashimoto's thyroiditis (HT), nodular goiter (NG), follicular adenoma (FA) and other types. However, the function of these diseases in PTC tumorigenesis and development is not well understood. In this research, 563 PTC patients were recruited and divided into two groups according to pathological diagnosis, namely simple PTC (PTC) and PTC combined with other thyroid diseases (PTC+). Clinicopathological characteristics and BRAF(V600E) mutation status were compared between PTC and PTC+. Our data showed that there was a statistically significant difference in gender (p=0.007), tumor diameter (5 mm, p=0.012; 1 cm, p=0.042), lymph node metastasis (p=0.000) and BRAF(V600E) mutation status (p=0.001) between PTC and PTC+. PTC+ patients have lower lymph node metastasis rate, even if PTC nodule diameter is larger than 5 mm (p=0.005) or =1 cm (p=0.049) or BRAF(V600E) is mutated (p=0.001). In conclusion, our study suggests that HT, NG and FA, are protective factors of PTC patients, and PTC+ patients have lower lymph node metastasis and BRAF(V600E) mutation rate compared with simple PTC patients.